Physician profile
Courtney Lynn Thomas
NPI 1063046662
$1,305.51
in general payments reported to CMS, 2019-2025
11 companies · $293 in 2025
The $293 reported for 2025 was more than what 93% of Neonatal, Critical Care providers received nationally (typical 2025 total: $45.50).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $101 · 2022: $384 · 2023: $130 · 2024: $397 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $820.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $310.76 | 2022-2025 | Polivy, Itovebi, Lunsumio |
| Takeda Pharmaceuticals U.S.A., INC. | $286.47 | 2024-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Genzyme Corporation | $218.08 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $196.32 | 2022-2025 | |
| Amgen INC. | $164.76 | 2022-2025 | Kyprolis, Kyprolis, Blincyto |
| Sobi, INC | $33.04 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $27.21 | 2023 | Pylarify |
| Janssen Biotech, INC. | $19.88 | 2021 | |
| Chiesi USA, INC. | $18.44 | 2021 | |
| Mallinckrodt Hospital Products INC. | $16.29 | 2021 | |
| Immunocore Limited | $14.26 | 2025 | Kimmtrak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Courtney Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.